Thank you skezan and Riz. Regardless the level of CCR5 overexpression between TNBC and CRC, I am confident the CRC trial was coordinated with KOL and will prove success. While CCR5 is obviously important for leronlimab, the elegant ability of macrophage repolarization and PD-L1 cold-to-hot MOA will prove successful in CRC (and many other cancers) IMO.